TITLE

Mirabegron -- promising new drug for overactive bladder syndrome

AUTHOR(S)
Rigby, Debbie
PUB. DATE
June 2015
SOURCE
Australian & New Zealand Continence Journal;Winter2015, Vol. 21 Issue 2, p40
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the potential therapeutic use of antimuscarinic agent Mirabegron in treating patients with urinary incontinence (UI) and overactive bladder (OAB) syndrome. Information regarding the drugs adverse health effects, prescribed dosage, and tolerance, are discussed. The article also mentioned the result of a clinical trial for the drug.
ACCESSION #
103624022

 

Related Articles

  • Mirabegron available to treat overactive bladder.  // British Journal of Hospital Medicine (17508460);Mar2013, Vol. 74 Issue 3, p129 

    The article reports that use of a first-in-class once-daily oral beta 3 adrenoceptor agonist Mirabegron in different treatments.

  • Overactive Bladder and the β-Adrenoceptor Agonists: Current Strategy and Future Prospects. Giarenis, Ilias; Robinson, Dudley; Cardozo, Linda // Drugs;Oct2015, Vol. 75 Issue 15, p1707 

    Overactive bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence, and is usually associated with frequency and nocturia. It is a common, under-diagnosed and therefore under-treated condition that can have a detrimental effect on...

  • Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome. Sanford, Mark // Drugs;2013, Vol. 73 Issue 11, p1213 

    Mirabegron (YM178, Myrbetriq™, Betanis, Betmiga™) is a β-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome. In three 12-week, randomized, double-blind, placebo-controlled, multinational trials in...

  • Presente y futuro del tratamiento farmacol�gico de la vejiga hiperactiva. Mu�oz G�lligo, E.; Garc�a Garc�a-Porrero, A.; Masero Casasola, A. R.; Mu�oz Garrido, F. // Suelo P�lvico;2012, Vol. 8 Issue 3, p64 

    The overactive bladder syndrome has a complex physiopathological basis, which implies muscular and neural systems and a complex array of molecular intermediaries. In fact, in our days the pharmacological treatment, based on anticholinergics drugs, is not effective in a great proportion of...

  • Prescribing beta-agonists for respiratory disease. Scullion, Jane; Holmes, Steve // Independent Nurse;4/16/2010, p1 

    The article discusses about beta-agonists which are commonly prescribed to relieve symptoms of asthma & chronic obstructive pulmonary disease(COPD), focusing on the difference in its usage for both the diseases and the modes of action. After the initiation of inhaled corticosteroids(ICS), long...

  • Mirabegron: a guide to its use in overactive bladder syndrome in the EU. Sanford, Mark; Lyseng-Williamson, Katherine // Drugs & Therapy Perspectives;Apr2015, Vol. 31 Issue 4, p107 

    Mirabegron (Betmiga™), a β-adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced...

  • Still cause for concern. Tattersfield, A.E. // BMJ: British Medical Journal (International Edition);9/24/94, Vol. 309 Issue 6957, p794 

    Focuses on the use of beta agonist on patients with asthma in the Great Britain. Mortality rate in the year 1960s and 1970s; Implication of high dosage of beta agonists on mortality rate from asthma; Suggestion of the morbidity study on the tolerance of beta agonist among asthma patients.

  • Adverse affects are not proved. Fuller, R.W. // BMJ: British Medical Journal (International Edition);9/24/94, Vol. 309 Issue 6957, p795 

    Focuses on the association of beta agonist to mortality rate from asthma. Acceptance of beta agonist as appropriate bronchodilator for asthma; Explanation on the association of beta agonist to mortality rate; Alternative hypothesis on the association of beta agonist to mortality rate. INSET:...

  • Researchers test drug to reduce scoliosis.  // Fairfield County Business Journal;04/28/97, Vol. 36 Issue 17, p18 

    Reports on the findings by three New York Medical College scientists on the effectiveness of the beta-2 agonist clenbuterol to reduce the scoliosis that develops in rat spines where the cords have been cut three-quarters of the way through.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics